Most writing about GLP-1 prices is organised by product: what Wegovy costs, what Zepbound costs, what the pill costs. That is the right shape for the question "what does this drug cost" and the wrong shape for the question people actually type, which is "what is the cheapest way for me to get one".
The reason is that almost every price in this market is gated. Read the programme terms rather than the price tables and a different structure appears: four eligibility states, largely mutually exclusive, each with its own set of available prices. Which state a person is in decides more about what they pay than which molecule they are prescribed.
This page is about the gates. The dated figures behind them are on our GLP-1 cost page, which prices every product from the manufacturers' own guides, and nothing in that table is repeated here.
The four states
| Eligibility state | What the terms require | What opens | What closes |
|---|---|---|---|
| No insurance | A valid prescription; an undertaking not to claim the cost from a third-party payer | Manufacturer self-pay through NovoCare and LillyDirect; retail and membership pricing | Every savings card, because each requires a commercial plan to exist |
| Commercial insurance that covers the drug | Commercial drug insurance; not enrolled in a government programme | The $25 copay cards, capped | Nothing, except the offers reserved for non-coverage |
| Commercial insurance that does not cover the drug | Commercial drug insurance that does not cover the product | Lilly's KwikPen savings tier, which exists for exactly this case | The $25 copay tier, which requires coverage |
| Medicare, Medicaid, TRICARE, VA or another government programme | Enrolment in the programme | The Medicare GLP-1 Bridge, if the prescriber attests and the criteria are met | Every manufacturer savings card, by name |
The fourth row is the one that surprises people, and it is the least ambiguous of the four. Lilly's Zepbound savings card terms, read on 2026-09-21, require that the patient is "not enrolled in any state, federal, or government funded healthcare program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE/CHAMPUS". Novo Nordisk's Wegovy price guide states it in four words, in a footnote to the copay column: "Government beneficiaries excluded."
Why the exclusion exists, which is not the reason most people assume
It is not a manufacturer's commercial preference. It is a consequence of 42 U.S.C. 1320a-7a(a)(5), which imposes a civil monetary penalty on a person who
"offers to or transfers remuneration to any individual eligible for benefits under subchapter XVIII of this chapter, or under a State health care program … that such person knows or should know is likely to influence such individual to order or receive from a particular provider, practitioner, or supplier any item or service for which payment may be made, in whole or in part, under subchapter XVIII, or a State health care program".
Subchapter XVIII is Medicare. A copay coupon is remuneration, and a coupon for a specific brand is by design likely to influence which item a patient obtains. So the coupon cannot lawfully be offered to a Medicare or Medicaid beneficiary, and every card in this class says so.
The provision was written to protect programme beneficiaries from being steered by inducements. Its effect in this particular market, where the government programmes largely exclude the weight-management indication anyway, is that a group with limited means is barred from the discount that a commercially insured patient can use. That is a consequence of a general rule meeting an unusual drug class, not evidence of anyone's bad faith — but it is the single most important fact about what a GLP-1 costs a person over 65, and it is almost never stated.
The offer that requires a denial
The third row is the oddity of the set, and it is an eligibility criterion no other drug class needs.
Lilly's terms, read on 2026-09-21, gate two prices for the same molecule on opposite answers to the same question. The savings card for the Zepbound single-dose pen requires commercial drug insurance that covers Zepbound. The savings offer for the single-patient-use KwikPen requires commercial drug insurance that does not cover Zepbound, and is capped at a maximum of 11 fills a year rather than 13.
So a coverage denial is not only a cost; in this one programme it is a qualification. A patient whose plan pays nothing becomes eligible for a manufacturer price that a patient with the same plan and a favourable formulary decision cannot use. The published self-pay figures attached to that tier, and the refill condition that lapses them, are on our Zepbound cost page.
The undertakings attached to self-pay
The self-pay route is the one with the fewest gates, and it is the only one open to a person with no insurance at all. It is not unconditional.
Novo Nordisk's price guide states that self-pay pricing "is available for local pharmacy pickup with a savings offer or home delivery", and prices the Wegovy pill and pen separately on that basis. Lilly's self-pay terms require the patient to agree that they "will not seek or accept reimbursement for any out-of-pocket costs … from any third-party payer" and will not use government programme benefits at the same time.
That undertaking is the mirror image of the coupon rule. A savings card requires a plan to exist; a self-pay price requires that no plan be used. The two cannot be combined, which is why a person cannot simply take whichever number is lower.
Two of these prices expire before the year ends
Both manufacturer offers read for this page are time-limited, and the limit is printed in the same footnote as the price.
Novo Nordisk's introductory price is described in its own price guide as covering "2 monthly fills through December 31, 2026, then $349 per month", and is restricted to "[p]atients new to Wegovy Savings Offer & NovoCare Pharmacy". Lilly's Zepbound savings card states that the card "expires and savings end on 12/31/2026". Both documents reserve the manufacturer's right to "modify or cancel this program at any time".
This is the practical case for reading the market by programme. A figure quoted in an article written three months ago may already belong to a programme that has changed; an eligibility state changes only when a person's circumstances or the law do.
The caps are on the saving, not on the price
A detail that decides whether a card is worth anything to a given person, and one the marketing language obscures.
Novo Nordisk's cards say "[p]ay as little as $25, subject to a maximum savings of $100/month". Lilly's Zepbound card is capped at up to $100 per one-month fill, $1,300 per calendar year and 13 fills. In each case the cap is on the manufacturer's contribution.
The arithmetic that follows is simple and rarely spelled out: if a plan's copay is $125, a $100 cap reaches the advertised $25. If the copay is $400, the same card leaves $300. The advertised number describes the best case a plan can produce, not the card's effect on any particular plan, and the difference between the two is entirely a function of the plan rather than of the card.
What this page does not establish
It does not tell any individual which route is cheapest for them, because that depends on a plan's formulary, a prescriber's judgement and a set of programme terms that both manufacturers reserve the right to change without notice. It does not restate the prices; those are dated on the cost hub and re-read there.
It also does not cover the state-by-state Medicaid position, which is genuinely variable and was not readable from a single source on the date of writing, and it does not assess any telehealth service's membership terms. The eligibility criteria quoted here were read from the manufacturers' own current terms and price guides on 2026-09-21; the statutory text was read from the United States Code the same day.
Sources and dates
- Novo Nordisk, Wegovy Price Guide, document code US26NC00049, April 2026 — read 2026-09-21 for the self-pay and copay columns and all three footnotes.
- Lilly, Zepbound coverage and savings terms — read 2026-09-21 for the savings-card eligibility list, the caps, the fill limits, the expiry and the self-pay undertaking.
- 42 U.S.C. § 1320a-7a(a)(5), civil monetary penalties, United States Code via govinfo.gov — read 2026-09-21.